Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyadic International, Inc. - Common Stock (NQ:DYAI)

1.265 -0.075 (-5.60%)
Streaming Delayed Price Updated: 2:50 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
From Dyadic International, Inc.
Via GlobeNewswire
Recap: Dyadic International Q1 Earnings
Dyadic International (NASDAQ:DYAI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Dyadic International: Q2 Earnings Insights
  Dyadic International (NASDAQ:DYAI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Preview: Dyadic International
  Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. 
Via Benzinga
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
From Dyadic International, Inc.
Via GlobeNewswire
India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform
Via Benzinga
Dyadic International Earnings Perspective: Return On Capital Employed
Dyadic International (NASDAQ:DYAI) brought in sales totaling $313.29 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 145.67%, resulting in a loss of $4.21... 
Via Benzinga
Why Phibro Shares Are Trading Higher Today?
Phibro Animal Health Corp (NASDAQ: PAHC) and Dyadic International Inc (NASDAQ: DYAI) have entered into an  
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million. 
Via Benzinga
A Preview Of Dyadic International's Earnings
Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Dyadic... 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
This Vaccine Stock Is Now On Janssen Pharmaceuticals, J&J, The White House's Radar
Dyadic International shares were up over 6% on January 3rd. Shares are up over 35% in the last month. 
Via Talk Markets
63 Biggest Movers From Friday
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Genfit (NASDAQ:GN... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. X4 Pharmaceuticals, Inc... 
Via Benzinga
This Company has its Sights Set of Transforming the Pharmaceutical Industry With its Efficient C1 Vaccine & Drug Manufacturing Technology
Photo by Testalize.me on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Dyadic International Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Dyadic International (NASDAQ:DYAI) reported Q2 sales of $937.09 thousand. Earnings fell to a loss of $3.85 million, resulting in a 16.92% decrease from last... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ: 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently... 
Via Benzinga
Market Briefing For Thursday, Aug. 26
Underperformance by many stocks, but few that are really in trouble, is reflective of rising complacency, while technicians are frustrated at the lack of breakouts or breakdowns. That's actually fine,... 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 100.19% to $30.63 during Wednesday's regular session. Regencell Bioscience's stock is trading at a volume of 8... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 64.84% to $6.33 during Monday's pre-market session. The market value of their outstanding shares is at $144... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA... 
Via Benzinga
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.